Palo Alto, CA, United States of America

Fangfang Shen

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Westlake University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fangfang Shen. Retrieved from https://idiyas.com/inventor/fangfang-shen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fangfang Shen - Innovator in Cancer Treatment

Introduction

Fangfang Shen is an accomplished inventor based in Palo Alto, California. She is currently affiliated with Westlake University, where she focuses on innovative research in the field of synthetic small molecules. Although she has not yet been granted any patents, her work holds significant promise for advancements in cancer treatment.

Latest Patent Applications

Fangfang Shen's notable patent application is titled "Aminoxy Acid-Based Anti-Cancer Stem Cell Compounds and Methods Thereof." This invention is centered around the development of synthetic small molecules that can be utilized as drugs, particularly for treating cancer. The application outlines methods for inhibiting cancer stem cells and provides approaches for treating various cancers and other diseases by affecting mitochondrial functions. Additionally, it details the methods for making and using these compounds.

Conclusion

Fangfang Shen's innovative research and patent application reflect her commitment to advancing cancer treatment through synthetic small molecules. Her contributions to the field are noteworthy, and her work may lead to significant breakthroughs in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…